Loading patent…
AssigneeCell Signaling Technology, Inc.
InventorsRoberto Polakiewicz, Valerie Goss, Albrecht Moritz, Ting-Lei Gu, Kimberly Lee
Estimating the term…
The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.
An isolated phosphorylation site-specific antibody that specifically binds a human CASC3 protein only when phosphorylated at the tyrosine at position 181, comprised within the phosphorylatable peptide sequence listed in SEQ ID NO:
An isolated phosphorylation site-specific antibody that specifically binds a human SLC29A4 protein only when phosphorylated at the tyrosine at position 198, comprised within the phosphorylatable peptide sequence listed in SEQ ID NO:
An isolated phosphorylation site-specific antibody that specifically binds a human CASC3 protein only when not phosphorylated at the tyrosine at position 181, comprised within the phosphorylatable peptide sequence listed in SEQ ID NO:
An isolated phosphorylation site-specific antibody that specifically binds a human SLC29A4 protein only when not phosphorylated at the tyrosine at position 198, comprised within the phosphorylatable peptide sequence listed in SEQ ID NO:
Dependencies are inferred from the claim text.